David Stroncek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Stroncek has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Jo L. Procter
From the Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, and the Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
3 shared publicationsSusan F. Leitman
Biostatistical Research Section, National Heart Lung Blood Institute, National Institutes of Health, Bethesda, Maryland
3 shared publicationsJuergen Bux
Institute for Clinical Immunology and Transfusion MedicineGiessen, Germany
2 shared publicationsK. Matsuo
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, NIH, Bethesda, Maryland 20892-1184, USA
2 shared publicationsKazuhiko Matsuo
From the Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, and the First Internal Medicine Department, Kurume University, Kurume, Fukuoka, Japan
2 shared publicationsLorraine Caruccio
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
2 shared publications
Latest Publications
- Open Access
- 26 May 2005
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 3 (1) , 1-8
Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides
The continuous efforts aimed at the identification of new immune epitopes across the MHC system has led to the discovery that more than one peptide may be restricted to the same HLA antigen and function as an immune determinant for that association. The aim of this study was to compare the ability of two overlapping peptides, the nonamer (9-mer) cytomegalovirus (CMV) pp65341–349 (QYDPVAALF) and the decamer (10-mer) CMV pp65341–350 (QYDPVAALFF), and the esadecamer (16-mer) peptide containing both the 9-mer and 10-mer sequences, CMV pp65340–355 (RQYDPVAALFFFDIDL), to stimulate and maintain over time a T cell immune reactivation by HLA-A*2402, A*0101, and Cw*0402 cells from CMV-seropositive subjects. The 9-mer, 10-mer, and 16-mer peptides effectively stimulated CTLs from HLA-A*2402, HLA-A*0101, and HLA-Cw*0402 CMV seropositive donors. This data confirms that both the 9-mer and the 10-mer peptides are promiscuous and are not restricted to a single HLA antigen. CMV pp65341–349 and CMV pp65341–350 have the ability to produce CMV-specific CTLs in subjects with several different HLA types, presenting a practical advantage over other peptides that are restricted only to a single HLA antigen, and thus being optimal for CMV adoptive immune therapy. Moreover, since the 16-mer peptide encompasses both the 9-mer and 10-mer peptides, it may be better than either of these peptides for CMV adoptive immune therapy.
- 26 May 2005
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 3 (1) , 1-8
Open AccessAnalysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides
The continuous efforts aimed at the identification of new immune epitopes across the MHC system has led to the discovery that more than one peptide may be restricted to the same HLA antigen and function as an immune determinant for that association. The aim of this study was to compare the ability of two overlapping peptides, the nonamer (9-mer) cytomegalovirus (CMV) pp65341–349 (QYDPVAALF) and the decamer (10-mer) CMV pp65341–350 (QYDPVAALFF), and the esadecamer (16-mer) peptide containing both the 9-mer and 10-mer sequences, CMV pp65340–355 (RQYDPVAALFFFDIDL), to stimulate and maintain over time a T cell immune reactivation by HLA-A*2402, A*0101, and Cw*0402 cells from CMV-seropositive subjects. The 9-mer, 10-mer, and 16-mer peptides effectively stimulated CTLs from HLA-A*2402, HLA-A*0101, and HLA-Cw*0402 CMV seropositive donors. This data confirms that both the 9-mer and the 10-mer peptides are promiscuous and are not restricted to a single HLA antigen. CMV pp65341–349 and CMV pp65341–350 have the ability to produce CMV-specific CTLs in subjects with several different HLA types, presenting a practical advantage over other peptides that are restricted only to a single HLA antigen, and thus being optimal for CMV adoptive immune therapy. Moreover, since the 16-mer peptide encompasses both the 9-mer and 10-mer peptides, it may be better than either of these peptides for CMV adoptive immune therapy.
- 13 January 2004
- Published by Wiley in Transfusion
- Vol. 44 (1) , 77-82
CD177 polymorphisms: correlation between high‐frequency single nucleotide polymorphisms and neutrophil surface protein expression
BACKGROUND: Human neutrophil antigen‐2a (NB1) is located on NB1 glycoprotein, which is expressed on subpopulations of neutrophils. PRV‐1 is a gene that is over‐expressed in neutrophils from patients with polycythemia rubra vera. The gene encoding NB1 differs from PRV‐1 at four nucleotides. The purpose of this study was to determine if PRV‐1 and NB1 are alleles of the same gene or two separate genes; and, moreover, if they are alleles, to explore potential correlations to NB1 glycoprotein expression.STUDY DESIGN AND METHODS: Primer pairs were used to amplify WBC DNA in the regions surrounding the four NB1 polymorphic sites. The four resulting amplicons were sequenced. The size of the neutrophil population in each donor that stained brightly with CD177 antibody was assessed by flow cytometry.RESULTS: If PRV‐1 and NB1 are separate genes, then all people should be heterozygous for the PRV‐1/NB1 polymorphisms. Because 11 of 23 donors were homozygous for PRV‐1 polymorphisms at all four sites, PRV‐1 and NB1 are alleles of the same gene, CD177. When the sequenced exons were compared with PRV‐1, 13 single nucleotide polymorphisms (SNPs) that result in amino acid changes were found. The G42C NB1 polymorphism, found in 10 donors, was the most common SNP. The size of the CD177 bright‐staining neutrophil population was greater in 42C/C donors than in 42G/G donors (66 ± 20% vs. 41 ± 21%, p = 0.004).CONCLUSIONS: PRV‐1 and NB1 are alleles of the polymorphic gene CD177. The most common SNP in bp 42 predicted an amino acid change that may have an effect on protein expression.
- 13 January 2004
- Published by Wiley in Transfusion
- Vol. 44 (1) , 77-82
CD177 polymorphisms: correlation between high‐frequency single nucleotide polymorphisms and neutrophil surface protein expression
BACKGROUND: Human neutrophil antigen‐2a (NB1) is located on NB1 glycoprotein, which is expressed on subpopulations of neutrophils. PRV‐1 is a gene that is over‐expressed in neutrophils from patients with polycythemia rubra vera. The gene encoding NB1 differs from PRV‐1 at four nucleotides. The purpose of this study was to determine if PRV‐1 and NB1 are alleles of the same gene or two separate genes; and, moreover, if they are alleles, to explore potential correlations to NB1 glycoprotein expression.STUDY DESIGN AND METHODS: Primer pairs were used to amplify WBC DNA in the regions surrounding the four NB1 polymorphic sites. The four resulting amplicons were sequenced. The size of the neutrophil population in each donor that stained brightly with CD177 antibody was assessed by flow cytometry.RESULTS: If PRV‐1 and NB1 are separate genes, then all people should be heterozygous for the PRV‐1/NB1 polymorphisms. Because 11 of 23 donors were homozygous for PRV‐1 polymorphisms at all four sites, PRV‐1 and NB1 are alleles of the same gene, CD177. When the sequenced exons were compared with PRV‐1, 13 single nucleotide polymorphisms (SNPs) that result in amino acid changes were found. The G42C NB1 polymorphism, found in 10 donors, was the most common SNP. The size of the CD177 bright‐staining neutrophil population was greater in 42C/C donors than in 42G/G donors (66 ± 20% vs. 41 ± 21%, p = 0.004).CONCLUSIONS: PRV‐1 and NB1 are alleles of the polymorphic gene CD177. The most common SNP in bp 42 predicted an amino acid change that may have an effect on protein expression.
- Open Access
- 1 June 2003
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 1 (1) , 12
Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR)
The identification and characterization of viral epitopes across the Human Leukocyte Antigen (HLA) polymorphism is critical for the development of actives-specific or adoptive immunotherapy of virally-mediated diseases. This work investigates whether cytokine mRNA transcripts could be used to identify epitope-specific HLA-restricted memory T lymphocytes reactivity directly in fresh peripheral blood mononuclear cells (PBMCs) from viral-seropositive individuals in response to ex vivo antigen recall. PBMCs from HLA-A*0201 healthy donors, seropositive for Cytomegalovirus (CMV) and Influenza (Flu), were exposed for different periods and at different cell concentrations to the HLA-A*0201-restricted viral FluM158–66 and CMVpp65495–503 peptides. Quantitative real time PCR (qRT-PCR) was employed to evaluate memory T lymphocyte immune reactivation by measuring the production of mRNA encoding four cytokines: Interferon-γ (IFN-γ), Interleukin-2 (IL-2), Interleukin-4 (IL-4), and Interleukin-10 (IL-10). We could characterize cytokine expression kinetics that illustrated how cytokine mRNA levels could be used as ex vivo indicators of T cell reactivity. Particularly, IFN-γ mRNA transcripts could be consistently detected within 3 to 12 hours of short-term stimulation in levels sufficient to screen for HLA-restricted viral immune responses in seropositive subjects. This strategy will enhance the efficiency of the identification of viral epitopes independently of the individual HLA phenotype and could be used to follow the intensity of immune responses during disease progression or in response to in vivo antigen-specific immunization.
- 1 June 2003
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 1 (1) , 12
Open AccessEx vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR)
The identification and characterization of viral epitopes across the Human Leukocyte Antigen (HLA) polymorphism is critical for the development of actives-specific or adoptive immunotherapy of virally-mediated diseases. This work investigates whether cytokine mRNA transcripts could be used to identify epitope-specific HLA-restricted memory T lymphocytes reactivity directly in fresh peripheral blood mononuclear cells (PBMCs) from viral-seropositive individuals in response to ex vivo antigen recall. PBMCs from HLA-A*0201 healthy donors, seropositive for Cytomegalovirus (CMV) and Influenza (Flu), were exposed for different periods and at different cell concentrations to the HLA-A*0201-restricted viral FluM158–66 and CMVpp65495–503 peptides. Quantitative real time PCR (qRT-PCR) was employed to evaluate memory T lymphocyte immune reactivation by measuring the production of mRNA encoding four cytokines: Interferon-γ (IFN-γ), Interleukin-2 (IL-2), Interleukin-4 (IL-4), and Interleukin-10 (IL-10). We could characterize cytokine expression kinetics that illustrated how cytokine mRNA levels could be used as ex vivo indicators of T cell reactivity. Particularly, IFN-γ mRNA transcripts could be consistently detected within 3 to 12 hours of short-term stimulation in levels sufficient to screen for HLA-restricted viral immune responses in seropositive subjects. This strategy will enhance the efficiency of the identification of viral epitopes independently of the individual HLA phenotype and could be used to follow the intensity of immune responses during disease progression or in response to in vivo antigen-specific immunization.
- 16 April 2003
- Published by Wiley in Transfusion
- Vol. 43 (5) , 609-613
G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donors
BACKGROUND : PBPC donors given G‐CSF experience splenic enlargement and, rarely, spontaneous rupture of the spleen. This study evaluated the incidence and time course of splenic enlargement in PBPC concentrate donors and assessed factors affecting size changes. STUDY DESIGN AND METHODS : Twenty healthy adults were given G‐CSF (10 μg/kg/day) for 5 days and a PBPC concentrate was collected by apheresis. Ultrasound was used to assess craniocaudal spleen length before giving G‐CSF, on the day of apheresis and 3 or 4 days after apheresis. The effects of donor age, gender, race, and changes in blood chemistries, blood counts, and CD34+ cell counts on spleen length change were assessed. RESULTS : Spleen length increased in 19 of 20 donors. Mean length changed from 10.9 ± 2.0 cm before G‐CSF to 12.3 ± 2.1 cm on the day of apheresis (p < 0.001). The mean increase in length was 1.5 ± 0.9 cm or 13.8 ± 9.1 percent. Spleen length increased 20 percent or more in six subjects. The spleen length fell to 11.3 ± 1.8 cm (p < 0.001) 3 or 4 days after apheresis, but it remained greater than baseline levels (p = 0.03). Spleen length change was not affected by donor gender, race, or age. There was no relationship between changes in spleen length and 1) baseline and apheresis‐day blood counts and chemistries, or 2) changes in blood counts and chemistries. CONCLUSIONS : Spleen size increases in almost all PBPC donors. Enlargement is transient but may be marked in some donors and may place them at risk for splenic rupture.
- 16 April 2003
- Published by Wiley in Transfusion
- Vol. 43 (5) , 609-613
G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donors
BACKGROUND : PBPC donors given G‐CSF experience splenic enlargement and, rarely, spontaneous rupture of the spleen. This study evaluated the incidence and time course of splenic enlargement in PBPC concentrate donors and assessed factors affecting size changes. STUDY DESIGN AND METHODS : Twenty healthy adults were given G‐CSF (10 μg/kg/day) for 5 days and a PBPC concentrate was collected by apheresis. Ultrasound was used to assess craniocaudal spleen length before giving G‐CSF, on the day of apheresis and 3 or 4 days after apheresis. The effects of donor age, gender, race, and changes in blood chemistries, blood counts, and CD34+ cell counts on spleen length change were assessed. RESULTS : Spleen length increased in 19 of 20 donors. Mean length changed from 10.9 ± 2.0 cm before G‐CSF to 12.3 ± 2.1 cm on the day of apheresis (p < 0.001). The mean increase in length was 1.5 ± 0.9 cm or 13.8 ± 9.1 percent. Spleen length increased 20 percent or more in six subjects. The spleen length fell to 11.3 ± 1.8 cm (p < 0.001) 3 or 4 days after apheresis, but it remained greater than baseline levels (p = 0.03). Spleen length change was not affected by donor gender, race, or age. There was no relationship between changes in spleen length and 1) baseline and apheresis‐day blood counts and chemistries, or 2) changes in blood counts and chemistries. CONCLUSIONS : Spleen size increases in almost all PBPC donors. Enlargement is transient but may be marked in some donors and may place them at risk for splenic rupture.
- 12 March 2003
- Published by Wiley in Transfusion
- Vol. 43 (3) , 357-363
Expression of human neutrophil antigen‐2a (NB1) is increased in pregnancy
BACKGROUND : The expression of human neutrophil antigen‐2a (HNA‐2a) or NB1 is highly variable. This study investigated variations in neutrophil expression of HNA‐2a by comparing the expression of epitopes recognized by three HNA‐2a‐specific CD177 antibodies among healthy adults and pregnant women. STUDY DESIGN AND METHODS : Flow cytometry was used to compare the neutrophil reactions of three CD177 antibodies (MEM‐166, TAG4, and 7D8) among 52 healthy adults. Because HNA‐2a expression is greater in women than men, neutrophils were studied from 21 women early in pregnancy and 23 women late in pregnancy. RESULTS : All three CD177 antibodies reacted with two populations of neutrophils: a brightly staining population and a dimly staining population. Among the 52 healthy adults, there was no difference in the mean size of the brightly reactive population of neutrophils recognized by each antibody (46 ± 23% for MEM‐166, 49 ± 23% for TAG4, and 49 ± 23% for 7D8), and all three antibodies were specific for HNA‐2a. For all three antibodies the size of the antigen bright neutrophil population was greater on neutrophils collected both early and late in pregnancy than in healthy adults. There was no difference in the size of the antigen bright population among neutrophils tested early and late in pregnancy. CONCLUSION : HNA‐2a antigen expression increases in pregnancy. Some of the variations in neutrophil expression of HNA‐2a among individuals is likely due to differences in gene regulation or differences in post‐translational protein modifications rather than gene polymorphisms.
- 12 March 2003
- Published by Wiley in Transfusion
- Vol. 43 (3) , 357-363
Expression of human neutrophil antigen‐2a (NB1) is increased in pregnancy
BACKGROUND : The expression of human neutrophil antigen‐2a (HNA‐2a) or NB1 is highly variable. This study investigated variations in neutrophil expression of HNA‐2a by comparing the expression of epitopes recognized by three HNA‐2a‐specific CD177 antibodies among healthy adults and pregnant women. STUDY DESIGN AND METHODS : Flow cytometry was used to compare the neutrophil reactions of three CD177 antibodies (MEM‐166, TAG4, and 7D8) among 52 healthy adults. Because HNA‐2a expression is greater in women than men, neutrophils were studied from 21 women early in pregnancy and 23 women late in pregnancy. RESULTS : All three CD177 antibodies reacted with two populations of neutrophils: a brightly staining population and a dimly staining population. Among the 52 healthy adults, there was no difference in the mean size of the brightly reactive population of neutrophils recognized by each antibody (46 ± 23% for MEM‐166, 49 ± 23% for TAG4, and 49 ± 23% for 7D8), and all three antibodies were specific for HNA‐2a. For all three antibodies the size of the antigen bright neutrophil population was greater on neutrophils collected both early and late in pregnancy than in healthy adults. There was no difference in the size of the antigen bright population among neutrophils tested early and late in pregnancy. CONCLUSION : HNA‐2a antigen expression increases in pregnancy. Some of the variations in neutrophil expression of HNA‐2a among individuals is likely due to differences in gene regulation or differences in post‐translational protein modifications rather than gene polymorphisms.
- 1 April 2002
- Published by Wiley in Transfusion
- Vol. 42 (4) , 393-395
Is it time to standardize granulocyte alloantigen nomenclature?
- 1 April 2002
- Published by Wiley in Transfusion
- Vol. 42 (4) , 393-395
Is it time to standardize granulocyte alloantigen nomenclature?
- 1 October 2001
- Published by Wiley in Transfusion
- Vol. 41 (10) , 1258-1262
Comparison of DATs using traditional tube agglutination to gel column and affinity column procedures
BACKGROUND: Detection of immunoglobulin or complement bound to RBCs by using the DAT is valuable in the diagnosis of immune‐mediated hemolytic anemia. Traditionally, the DAT has been performed by tube agglutination using anti‐IgG or anti‐C3d. The purpose of this study was to compare the tube agglutination DAT to gel microcolumn, affinity microcolumn, and flow cytometric DATs on RBCs coated in vitro and on patient RBC samples.STUDY DESIGN AND METHODS: RBCs from 84 patients were assessed by tube agglutination DAT, one gel microcolumn DAT, and two affinity microcolumn DATs. One affinity microcolumn assay was unmodified and one was modified by the addition of polyspecific antiglobulin or anti‐IgG as a secondary antibody. RBCs from 15 of the 84 patients underwent analysis by flow cytometry with fluorescence‐labeled anti‐IgG. The assays were also compared by using D+ RBCs sensitized with serially adjusted concentrations of anti‐D.RESULTS: Both tube agglutination and gel microcolumn DATs were positive in 49 patient samples; both assays were negative in 20 samples, and the results were discordant in 15. Gel microcolumn DATs were more likely than were tube agglutination DATs to detect IgG on RBCs. Affinity microcolumn DATs were less likely than gel microcolumn or tube agglutination DATs to detect IgG on RBCs. Flow cytometry results were the same as gel microcolumn results in 12 of 15 patient samples and the same as tube agglutination results in 13 of 15. Tube agglutination and both affinity microcolumn assays reacted with RBCs coated with anti‐D that was diluted 1‐in‐100. The gel microcolumn and flow cytometry assays reacted with RBCs coated with anti‐D diluted 1‐in‐400. There was no correlation between tube agglutination and gel microcolumn DATs in detecting bound C3d.CONCLUSION: Detection of IgG bound to RBCs was not consistent with the methods described. Gel microcolumn DATs were more sensitive than tube agglutination and affinity microcolumn DATs. Given the varied results of these assays, reference laboratories should not rely on a single method for DATs. More comprehensive testing should be performed when the tube agglutination DAT is negative in a patient with suspected immune‐mediated hemolytic anemia. Further comparisons are necessary to determine the proficiency of flow cytometric assays.
- 1 October 2001
- Published by Wiley in Transfusion
- Vol. 41 (10) , 1258-1262
Comparison of DATs using traditional tube agglutination to gel column and affinity column procedures
BACKGROUND: Detection of immunoglobulin or complement bound to RBCs by using the DAT is valuable in the diagnosis of immune‐mediated hemolytic anemia. Traditionally, the DAT has been performed by tube agglutination using anti‐IgG or anti‐C3d. The purpose of this study was to compare the tube agglutination DAT to gel microcolumn, affinity microcolumn, and flow cytometric DATs on RBCs coated in vitro and on patient RBC samples.STUDY DESIGN AND METHODS: RBCs from 84 patients were assessed by tube agglutination DAT, one gel microcolumn DAT, and two affinity microcolumn DATs. One affinity microcolumn assay was unmodified and one was modified by the addition of polyspecific antiglobulin or anti‐IgG as a secondary antibody. RBCs from 15 of the 84 patients underwent analysis by flow cytometry with fluorescence‐labeled anti‐IgG. The assays were also compared by using D+ RBCs sensitized with serially adjusted concentrations of anti‐D.RESULTS: Both tube agglutination and gel microcolumn DATs were positive in 49 patient samples; both assays were negative in 20 samples, and the results were discordant in 15. Gel microcolumn DATs were more likely than were tube agglutination DATs to detect IgG on RBCs. Affinity microcolumn DATs were less likely than gel microcolumn or tube agglutination DATs to detect IgG on RBCs. Flow cytometry results were the same as gel microcolumn results in 12 of 15 patient samples and the same as tube agglutination results in 13 of 15. Tube agglutination and both affinity microcolumn assays reacted with RBCs coated with anti‐D that was diluted 1‐in‐100. The gel microcolumn and flow cytometry assays reacted with RBCs coated with anti‐D diluted 1‐in‐400. There was no correlation between tube agglutination and gel microcolumn DATs in detecting bound C3d.CONCLUSION: Detection of IgG bound to RBCs was not consistent with the methods described. Gel microcolumn DATs were more sensitive than tube agglutination and affinity microcolumn DATs. Given the varied results of these assays, reference laboratories should not rely on a single method for DATs. More comprehensive testing should be performed when the tube agglutination DAT is negative in a patient with suspected immune‐mediated hemolytic anemia. Further comparisons are necessary to determine the proficiency of flow cytometric assays.
- 1 August 2001
- Published by Wiley in Transfusion
- Vol. 41 (8) , 1037-1044
Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF alone
BACKGROUND: G–CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G–CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.STUDY DESIGN AND METHODS: Twenty donors were studied on three occasions. They were given either dexamethasone (8 mg, by mouth) plus a placebo injection, G–CSF (5 μg/kg, given subcutaneously) plus placebo capsules, or G–CSF plus dexamethasone. Granulocytes were collected by apheresis. A donor symptom survey was administered, and cell counts and blood chemistries were assessed before collection and 1, 2, 7, 14, 21, 28, and 35 days after collection.RESULTS: More granulocytes were collected when G–CSF was given than when dexamethasone was given (41.1 ± 20.4 × 109 vs. 21.0 ± 10.0 × 109; p9; pCONCLUSION: These results support the use of G–CSF plus dexamethasone in granulocyte donors. G–CSF plus dexamethasone resulted in greater granulocyte yields than either agent alone and was associated with donor symptoms and changes in blood cell counts and chemistries similar to those seen with G–CSF alone or dexamethasone alone. Granulocytes can be safely collected a second time after a 7‐day interval; however, for regular donors, it may be best to separate collections by 4 weeks.
- 1 August 2001
- Published by Wiley in Transfusion
- Vol. 41 (8) , 1037-1044
Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF alone
BACKGROUND: G–CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G–CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.STUDY DESIGN AND METHODS: Twenty donors were studied on three occasions. They were given either dexamethasone (8 mg, by mouth) plus a placebo injection, G–CSF (5 μg/kg, given subcutaneously) plus placebo capsules, or G–CSF plus dexamethasone. Granulocytes were collected by apheresis. A donor symptom survey was administered, and cell counts and blood chemistries were assessed before collection and 1, 2, 7, 14, 21, 28, and 35 days after collection.RESULTS: More granulocytes were collected when G–CSF was given than when dexamethasone was given (41.1 ± 20.4 × 109 vs. 21.0 ± 10.0 × 109; p9; pCONCLUSION: These results support the use of G–CSF plus dexamethasone in granulocyte donors. G–CSF plus dexamethasone resulted in greater granulocyte yields than either agent alone and was associated with donor symptoms and changes in blood cell counts and chemistries similar to those seen with G–CSF alone or dexamethasone alone. Granulocytes can be safely collected a second time after a 7‐day interval; however, for regular donors, it may be best to separate collections by 4 weeks.
- 1 June 2001
- Published by Wiley in Transfusion
- Vol. 41 (6) , 775-782
The expression of NA antigens in people withunusual Fcγ receptor III genotypes
BACKGROUND: The Fcγ receptor IIIb (FcγRIIIB) genes that encode neutrophil‐specific antigens NA1 and NA2 differ at 5 nucleotides (nts); in 4, the result is an amino acid (AA) difference between the two alleles. The role of each of these differences in antigen expression is not known. Persons with FcγRIIIB genes that differ from NA1‐FcγRIIIB and NA2‐FcγRIIIB by 1 nt have been described. This study compared NA1 and NA2 expression on granulocytes in persons with variant FcγRIIIB genes and in healthy blood donors.STUDY DESIGN AND METHODS: Reactions of NA1‐ and NA2‐specific MoAbs and alloantibodies with granulocytes were assessed by flow cytometry in 74 healthy blood donors and 6 persons with known variant FcγRIIIB genes. The granulocytes were tested with 1 NA1‐specific MoAb, 1 NA2‐specific MoAb, 4 NA1‐specific alloantibodies, and 4 NA2‐specific alloantibodies.RESULTS: Analysis of granulocytes from persons with variant NA genotypes found that single‐base substitutions in FcγRIIIB at 141 and at 349 are important in NA1 expression and those at 227 and 277 are important in NA2 expression. Among blood donors, neither age, sex, nor race affected the expression of NA1 or NA2. The NA2‐specific MoAb reacted more intensely with granulocytes from NA2‐double‐dose cells than with those from NA‐single‐dose cells, but this was not true for the NA2‐specific alloantibodies. There was no difference in the reactions of the NA1‐specific MoAbs and alloantibodies with donor samples of known NA1‐double‐dose or NA‐single‐dose cells. The intensity of reactions of both the NA1‐ and NA2‐specific MoAbs and alloantibodies were strongly correlated on double‐dose cells but not on single‐dose cells. In fact, granulocytes from 7 healthy blood donors, phenotyped as NA‐single‐dose with the MoAbs, were phenotyped as NA2‐double‐dose with the alloantibodies. Variations in FcγRIIIB are common in blacks, but 5 of the 6 donors were white. These results suggest that FcγRIIIB variations may be common in both whites and blacks.CONCLUSIONS : NA2 expression is affected by polymorphisms in FcγRIIIB 227 and FcγRIIIB 277, both of which are involved in an FcγRIIIb N‐glycosylation site. Polymorphisms in FcγRIIIB at 141 and 349 appear more important to NA1 expression.
- 1 June 2001
- Published by Wiley in Transfusion
- Vol. 41 (6) , 775-782
The expression of NA antigens in people withunusual Fcγ receptor III genotypes
BACKGROUND: The Fcγ receptor IIIb (FcγRIIIB) genes that encode neutrophil‐specific antigens NA1 and NA2 differ at 5 nucleotides (nts); in 4, the result is an amino acid (AA) difference between the two alleles. The role of each of these differences in antigen expression is not known. Persons with FcγRIIIB genes that differ from NA1‐FcγRIIIB and NA2‐FcγRIIIB by 1 nt have been described. This study compared NA1 and NA2 expression on granulocytes in persons with variant FcγRIIIB genes and in healthy blood donors.STUDY DESIGN AND METHODS: Reactions of NA1‐ and NA2‐specific MoAbs and alloantibodies with granulocytes were assessed by flow cytometry in 74 healthy blood donors and 6 persons with known variant FcγRIIIB genes. The granulocytes were tested with 1 NA1‐specific MoAb, 1 NA2‐specific MoAb, 4 NA1‐specific alloantibodies, and 4 NA2‐specific alloantibodies.RESULTS: Analysis of granulocytes from persons with variant NA genotypes found that single‐base substitutions in FcγRIIIB at 141 and at 349 are important in NA1 expression and those at 227 and 277 are important in NA2 expression. Among blood donors, neither age, sex, nor race affected the expression of NA1 or NA2. The NA2‐specific MoAb reacted more intensely with granulocytes from NA2‐double‐dose cells than with those from NA‐single‐dose cells, but this was not true for the NA2‐specific alloantibodies. There was no difference in the reactions of the NA1‐specific MoAbs and alloantibodies with donor samples of known NA1‐double‐dose or NA‐single‐dose cells. The intensity of reactions of both the NA1‐ and NA2‐specific MoAbs and alloantibodies were strongly correlated on double‐dose cells but not on single‐dose cells. In fact, granulocytes from 7 healthy blood donors, phenotyped as NA‐single‐dose with the MoAbs, were phenotyped as NA2‐double‐dose with the alloantibodies. Variations in FcγRIIIB are common in blacks, but 5 of the 6 donors were white. These results suggest that FcγRIIIB variations may be common in both whites and blacks.CONCLUSIONS : NA2 expression is affected by polymorphisms in FcγRIIIB 227 and FcγRIIIB 277, both of which are involved in an FcγRIIIb N‐glycosylation site. Polymorphisms in FcγRIIIB at 141 and 349 appear more important to NA1 expression.